07/02/2022 – AB Science will deliver a presentation on the Amyotrophic Lateral Sclerosis (ALS) masitinib development program at the 2022 ALS Drug Development Summit Download PDF Post navigationPreviousPrevious post:AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products AgencyNextNext post:Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)Related PostsAB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosisDecember 29, 2022Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in SwitzerlandDecember 27, 2022AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment BankDecember 22, 2022AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)December 13, 2022AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosisDecember 29, 2022
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in SwitzerlandDecember 27, 2022
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment BankDecember 22, 2022
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)December 13, 2022
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022
